CNS Tumor

18 registered clinical trials studyying CNS Tumor — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS NCT06528691	St. Jude Children's Research Hospital	Phase 2
Recruiting	Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors NCT07236840	Tata Memorial Centre	—
Completed	Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent NCT06322342	Reveal Pharmaceuticals Inc.	Phase 2
Withdrawn	Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant NCT05952687	St. Jude Children's Research Hospital	Phase 1
Recruiting	Artificial Intelligence in CNS Radiation Oncology NCT06036394	Tata Memorial Centre	—
Recruiting	Characterizing Sleep Among Long-term Survivors of Childhood Cancer NCT05480904	St. Jude Children's Research Hospital	—
Recruiting	Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors NCT05982691	National Cancer Center, Korea	—
Unknown	Artificial Intelligence Neuropathologist NCT05300113	Huashan Hospital	—
Completed	A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling NCT04773782	Blueprint Medicines Corporation	Phase 1 / Phase 2
Withdrawn	Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade G NCT05222165	Helsinn Healthcare SA	Phase 1 / Phase 2
Recruiting	ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS NCT04732065	Sabine Mueller, MD, PhD	Phase 1
Active Not Recruiting	Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer NCT04706676	Rigshospitalet, Denmark	N/A
Recruiting	INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies NCT03838042	University Hospital Heidelberg	Phase 1 / Phase 2
Completed	Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescen NCT04023669	St. Jude Children's Research Hospital	Phase 1
Completed	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies fo NCT03434262	St. Jude Children's Research Hospital	Phase 1
Completed	Effectiveness of Care in Certified Cancer Centres in Germany NCT04334239	Technische Universität Dresden	—
Completed	Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry NCT02684838	Arbor Pharmaceuticals, Inc.	—
Terminated	Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma NCT02988726	Burzynski Research Institute	Phase 2